Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Day One Biopharmaceuticals (DAWN) EPS (Weighted Average and Diluted) (2022 - 2025)

Day One Biopharmaceuticals (DAWN) has disclosed EPS (Weighted Average and Diluted) for 4 consecutive years, with -$0.21 as the latest value for Q4 2025.

  • Quarterly EPS (Weighted Average and Diluted) rose 69.57% to -$0.21 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$1.04 through Dec 2025, up 3.7% year-over-year, with the annual reading at -$1.04 for FY2025, 1.96% down from the prior year.
  • EPS (Weighted Average and Diluted) for Q4 2025 was -$0.21 at Day One Biopharmaceuticals, down from -$0.19 in the prior quarter.
  • The five-year high for EPS (Weighted Average and Diluted) was $0.38 in Q3 2024, with the low at -$0.72 in Q1 2024.
  • Average EPS (Weighted Average and Diluted) over 4 years is -$0.42, with a median of -$0.54 recorded in 2022.
  • The sharpest move saw EPS (Weighted Average and Diluted) surged 170.37% in 2024, then plummeted 480.0% in 2025.
  • Over 4 years, EPS (Weighted Average and Diluted) stood at -$0.56 in 2022, then dropped by 14.29% to -$0.64 in 2023, then fell by 7.81% to -$0.69 in 2024, then surged by 69.57% to -$0.21 in 2025.
  • According to Business Quant data, EPS (Weighted Average and Diluted) over the past three periods came in at -$0.21, -$0.19, and -$0.29 for Q4 2025, Q3 2025, and Q2 2025 respectively.